Eterna Therapeutics appoints Sandra Gurrola as PFO; CFO Jackson resigns with $207,500 severance

Ernexa Therapeutics Inc.

Andrew Jackson resigned as CFO effective May 4, 2023; receives $207,500 salary continuation for 6 months plus COBRA premiums.
Sandra Gurrola appointed as principal financial officer effective May 5, 2023; she was previously VP Finance.
Jackson forfeited 33,239 unvested stock options granted June 3, 2022.
Separation agreement includes general release, cooperation, and confidentiality provisions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Jackson

Chief Financial Officer

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-05-04
Successor: Sandra Gurrola
Filed: May 5, 2023, 7:59 PM ET

Mr. Jackson resigned from his position as Chief Financial Officer (principal financial officer) and as an officer, director, manager or employee of the Company’s subsidiaries.

Appointed

Sandra Gurrola

principal financial officer

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-05-05
Filed: May 5, 2023, 7:59 PM ET

appointed Sandra Gurrola, the Company’s current Vice President, Finance (and principal accounting officer), as the Company’s principal financial officer, which appointment became effective on May 5, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Jackson resigned as Chief Financial Officer at Ernexa Therapeutics Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Mr. Jackson resigned from his position as Chief Financial Officer (principal financial officer) and as an officer, director, manager or employee of the Company’s subsidiaries.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra Gurrola was appointed as principal financial officer at Ernexa Therapeutics Inc..

Action: appointed
Role: principal financial officer

Exact text from the filing

appointed Sandra Gurrola, the Company’s current Vice President, Finance (and principal accounting officer), as the Company’s principal financial officer, which appointment became effective on May 5, 2023.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-023068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.